Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
Ralf‐Dieter Hofheinz(University of Mannheim), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Claudia Pauligk(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Georg Martin Haag(Heidelberg University), Matthias Ebert(University of Mannheim), Disorn Sookthai(Krankenhaus Nordwest), Daniel Pink(Universitätsmedizin Greifswald), Wolf O. Bechstein(Unknown), Rolf Mahlberg(Klinikum Mutterhaus der Borromäerinnen), Peter Reichardt(Helios Hospital Berlin-Buch), Thomas J. Ettrich(Universität Ulm), K Borchert(University Hospital Magdeburg), Gabriele Margareta Siegler(Nuremberg Hospital), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Albrecht Kretzschmar(Roche (Switzerland)), Christian Teschendorf(St. Josefs Hospital), Manfred Welslau(Klinikum Aschaffenburg), Timo Gaiser(University of Mannheim)
Cited by 91
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k